We are developing MR software using patented techniques to track and visualize device and tissue in 3D and real-time to improve health outcomes and reduce procedure times. Our technology is vendor agnostic, such that it will work with any combination of MRI and MR-compatible device. The beachhead market we are targeting is ventricular tachycardia as that is our group’s expertise and the market is not as saturated compared to other markets. After we prove the efficacy of our software, we will branch out to other indications, like atrial fibrillation, intracardiac tissue drug delivery, and cancer biopsy/target treatments.